In the recent phase III KEYNOTE-598 study, however, adding ipilimumab to pembrolizumab failed to improve efficacy and was associated with greater toxicity than pembrolizumab monotherapy as first-line treatment for metastatic NSCLC with PD-L1 TPS ≥ 50% and no targetable EGFR or ALK aberrations [43]. Here, ALK is linked to non-small cell lung carcinoma.